Bavarian Nordic makes major investment in domestic vaccine production  

The Danish biotech company acquires production plant in Zealand for DKK 250 million to establish vaccine production

Danish biotech company Bavarian Nordic has acquired a pharmaceutical production plant for DKK 250 million (USD 40 million) in northern Zealand from Finland's Orion Pharma to establish production of vaccines. The investment covers the acquisition of 2.6 hectares of land and existing buildings as well as the necessary rebuilding. According to Bavarian Nordic the plant will be one of Europe's largest production plants for vaccines with a capacity of up to 120 million doses a year. Up to 130 jobs are expected to be created.


MD Peter Wulff regards the acquisition as a milestone in Bavarian Nordic's transformation from a biotech company into pharmaceutical manufacturer. The new vaccine facility will come on stream in 2005 and initially will produce smallpox vaccines for the US and European markets along with various planned vaccines against HIV. Bavarian Nordic will move its HQ to the new plant while the clinical trial materials facility will remain in Berlin. The news is reported by BiotechDenmark online.


Link > Bavarian Nordic

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×